ReviewHepatology communications2025
Bioartificial liver: Where lies the path ahead-A review.
Review in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Exploring the efficacy and safety profile of the use of a heparin-free integrated tandem pre-flushing method for DPMAS treatment in patients with liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Observational
- Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its proven effectiveness in treating liver failure, liver transplantation is often impractical due to its high surgical risks involved and the limited availability of donor organs. Blood purification technologies used in non-bioartificial liver (NBAL) systems have improved clinical cure rates, but they do not substitute for the complex biosynthesis, detoxification, metabolism, and biological transformation roles of the liver. To overcome these challenges brought by NBAL systems, bioartificial liver (BAL) systems have been developed with repeated optimization of both hepatocyte sources and bioreactors to emulate a "fully functional liver"." Large biomedical research centers are eager to conduct clinical trials on the developing BAL systems to validate their safety and efficacy, and eventually bring BAL systems to market for clinical practice. Notably, the successful xenotransplantation of genetically modified porcine livers has provided valuable insights for the novel BAL system design. Chinese researchers have established a progressive series of world-first milestones in pig-to-human liver transplantation. Attempts to create genetically modified porcine BAL systems are promising to explore a path for solving the problem of seeking the most ideal cell sources and bioreactors. This review outlines the current clinical application of artificial liver support systems and summarizes the innovative advancements in BAL technology. Prospects of genetically modified porcine BAL systems are adequately discussed, with the expectation that multidisciplinary collaboration in BAL research will yield more promising therapeutic options for liver failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.